The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
The companies claimed that this machine could peel and cut an avocado in less than 30 seconds and operate unattended on a large batch, which could significantly reduce the time and labor required to prepare large quantities of guacamole. Chipotle's share price fell more than 9% after fiscal second quarter results showed same-store sales shrinking by 4%, compared to 0.4% in the prior quarter. In April 2025, Chipotle announced the opening of a location in Mexico by early 2026, looking to expand into new markets in the region. In August 2025, Chipotle announced plans of delivering food via drone aircraft within the greater Dallas area through a partnership with Zipline. In July 2026, Chipotle opened its first restaurant in Mexico in San Pedro Garza Garcia, Nuevo Leon, in partnership with Alsea. The company planned additional restaurants in Nuevo Leon during 2026 and an expansion into Mexico City in 2027. In August 2026, Chipotle opened its first restaurant in Saudi Arabia, in Riyadh, through a franchise partnership with Alshaya Group. In September 2026, Chipotle opened its first restaurant in South Korea, in the Gangnam District, via a joint venture with SPC Group.
mRNA vaccines offer specific advantages over traditional vaccines. Because mRNA vaccines are not constructed from an active pathogen (or even an inactivated pathogen), they are non-infectious. In contrast, traditional vaccines require the production of pathogens, which, if done at high volumes, could increase the risks of localized outbreaks of the virus at the production facility. Another biological advantage of mRNA vaccines is that since the antigens are produced inside the cell, they stimulate cellular immunity, as well as humoral immunity. mRNA vaccines have the production advantage that they can be designed swiftly. Moderna designed their mRNA-1273 vaccine for COVID-19 in 2 days. They can also be manufactured faster, more cheaply, and in a more standardized fashion (with fewer error rates in production), which can improve responsiveness to serious outbreaks. The Pfizer–BioNTech vaccine originally required 110 days to mass-produce (before Pfizer began to optimize the manufacturing process to only 60 days), which was substantially faster than traditional flu and polio vaccines. Within that larger timeframe, the actual production time is only about 22 days: two weeks for molecular cloning of DNA plasmids and purification of DNA, four days for DNA-to-RNA transcription and purification of mRNA, and four days to encapsulate mRNA in lipid nanoparticles followed by fill and finish. The majority of the days needed for each production run are allocated to rigorous quality control at each stage.
==== Methylation-sensitive single-strand conformation analysis (MS-SSCA) ==== This method is based on the single-strand conformation polymorphism analysis (SSCA) method developed for single-nucleotide polymorphism (SNP) analysis. SSCA differentiates between single-stranded DNA fragments of identical size but distinct sequence based on differential migration in non-denaturating electrophoresis. In MS-SSCA, this is used to distinguish between bisulfite-treated, PCR-amplified regions containing the CpG sites of interest. Although SSCA lacks sensitivity when only a single nucleotide difference is present, bisulfite treatment frequently makes a number of C-to-T conversions in most regions of interest, and the resulting sensitivity approaches 100%. MS-SSCA also provides semi-quantitative analysis of the degree of DNA methylation based on the ratio of band intensities. However, this method is designed to assess all CpG sites as a whole in the region of interest rather than individual methylation sites.
Bokkoms is whole, salted and dried mullet and is a well-known speciality the West Coast region of South Africa. This salted fish is dried in the sun and wind and is eaten after peeling off the skin. In some cases it is also smoked.
==== Skin conditions ==== UV rays also treat certain skin conditions. Modern phototherapy has been used to successfully treat psoriasis, eczema, jaundice, vitiligo, atopic dermatitis, and localized scleroderma. In addition, UV radiation, in particular UVB radiation, has been shown to induce cell cycle arrest in keratinocytes, the most common type of skin cell. As such, sunlight therapy can be a candidate for treatment of conditions such as psoriasis and exfoliative cheilitis, conditions in which skin cells divide more rapidly than usual or necessary.
Sources: en.wikipedia.org
== Terminology == In 1901, Jōkichi Takamine patented a purified extract from the adrenal glands, which was trademarked by Parke, Davis & Co in the US. The British Approved Name and European Pharmacopoeia term for this drug is hence adrenaline (from Latin ad, "on", and rēnālis, "of the kidney", from ren, "kidney"). However, the pharmacologist John Abel had already prepared an extract from adrenal glands as early as 1897, and he coined the name epinephrine to describe it (from Ancient Greek ἐπῐ́ (epí), "upon", and νεφρός (nephrós), "kidney"). As the term Adrenaline was a registered trademark in the US, and in the belief that Abel's extract was the same as Takamine's (a belief since disputed), epinephrine instead became the generic name used in the US and remains the pharmaceutical's United States Adopted Name and International Nonproprietary Name (though the name adrenaline is frequently used). The terminology is now one of the few differences between the INN and BAN systems of names. Although European health professionals and scientists preferentially use the term adrenaline, the converse is true among American health professionals and scientists. Nevertheless, even among the latter, receptors for this substance are called adrenergic receptors or adrenoceptors, and pharmaceuticals that mimic its effects are often called adrenergics. The history of adrenaline and epinephrine is reviewed by Rao.
=== Bioactive molecule layer === Finally, the bioactive molecule of interest is loaded into the carbohydrate layer. This process typically occurs through either lyophilization or passive adsorption, and the fully functionalized aquasome is then characterized.
== Legacy == During his post-doctoral days in the US, Rao's researches were focused on the synthesis of melanin pigments as well as on the carcinoma cells of human breast and the cross-talk between growth factor and steroid receptors. The group led by him is credited with the discovery of a novel subset of IgD receptors on 'naive' B lymphocytes which helped in a wider understanding of antigen-specific B cell selection and amplification. Later, furthering his earlier researches, he worked on designing new synthetic peptide vaccines for Hepatitis B which were reported to generate high immunogenicity in humans. He is also known to have contributed in the pathogenesis of Mycobacterium tuberculosis and in the diagnostics of HIV/AIDS. It was during his period with Virander Singh Chauhan and Ranjan Kumar Nanda at ICGEB, the group developed an electronic nose, a urine test, to monitor the progress of tuberculosis therapy. His current assignments are on the study of plasticity controlling mechanisms in receptor-initiated signaling pathways based on the systems level analysis of the antigen receptor-dependent signal transduction network. His research findings have been published as a number of articles; . He chaired U-EXCEL 2012, a task force of the Department of Biotechnology, for the North-eastern region of India and is a member of the Science and Engineering Research Board of the Department of Science and Technology. He is associated with the Institute of Life Sciences, Bhubaneswar as a member of its Scientific Advisory Committee and has delivered lectures on its behalf.
Degradation of an amino acid often begins with transamination, in which its amino group is transferred to α-ketoglutarate, forming glutamate. This process involves transaminases, often the same enzymes used in amino acid synthesis. In many vertebrates, the amino group is subsequently released as ammonia and converted to urea via the urea cycle for excretion. However, amino acid degradation can result in uric acid or ammonia instead, depending on the organism. For example, serine dehydratase converts serine directly to pyruvate and ammonia. After removal of one or more amino groups, the remaining carbon skeleton of an amino acid can serve as a precursor for synthesizing other amino acids, be further metabolized for energy after conversion into intermediates of glycolysis (typically via gluconeogenesis) or of the citric acid cycle, or be used for fatty acid synthesis and storage as triacylglycerol.
Sources: en.wikipedia.org
== Society == In 2013, the US Congress passed the Recalcitrant Cancer Research Act, which mandated increased attention to certain recalcitrant cancers (cancers having a 5-year relative survival rate of less than 50%), including small cell lung cancer. That led to the National Cancer Institute supporting small cell-specific research.
S2CID 17336375. Wickramasinghe, N. C. (2010). "The astrobiological case for our cosmic ancestry". International Journal of Astrobiology. 9 (2): 119–129. Bibcode:2010IJAsB...9..119W. doi:10.1017/S1473550409990413. S2CID 13978227. Wickramasinghe, N.C.; Wallis, J.; Wallis, D.H.; Schild, R.E.; Gibson, C.H. (2012). "Life-bearing planets in the solar vicinity". Astrophysics and Space Science. 341 (2): 295–9. Bibcode:2012Ap&SS.341..295W. doi:10.1007/s10509-012-1092-8. S2CID 120484953. Chandra Wickramasinghe, A Journey with Fred Hoyle: The Search for Cosmic Life, World Scientific Publishing, 2005, ISBN 981-238-912-1 Janaki Wickramasinghe, Chandra Wickramasinghe and William Napier, Comets and the Origin of Life, World Scientific Publishing, 2009, ISBN 981-256-635-X Chandra Wickramasinghe and Daisaku Ikeda, Space and Eternal Life, Journeyman Press, 1998, ISBN 1-85172-060-X
Gindilis, there are two criteria for a signal to be called artificial: one related to the artificial nature of the source and the other related to a particular radiation, intentionally designed to ensure communication and facilitate detection. Only Type II or III civilizations can communicate using isotropic transmissions that allow omnidirectional reception. In a 1 MHz band (which requires about 1024 watts), detection of signals from a Type II civilization is possible up to 1,000 light-years away, while signals from a Type III civilization are detectable virtually throughout the observable Universe. However, building an omnidirectional transmitter powerful enough to transmit over a range of 1,000 light years would take several million years. According to V.S. Troitsky, the energy required and the limitations in its production would be two obstacles to completing this project in a reasonable time. For Zoltan Galántai, we would not be able to distinguish between an intelligent extraterrestrial signal and a signal of natural origin. Therefore, he does not believe that Type II, III or even IV civilizations can be detected. Even if humanity reaches Type IV, it will not be able to detect another supercivilization of a similar level, and we will consider their changes in the universe to be the result of natural causes. Thus, there may be many Type IV civilizations in the universe, but none of them will be able to detect the others. Moreover, the dimensions of the universe make these supercivilizations like islands far from the others, which Dyson defines as a "Carroll Universe".
== Acneiform eruptions == Acneiform eruptions are caused by changes in the pilosebaceous unit. Acne aestivalis (Mallorca acne) Acne conglobata Acne cosmetica (cosmetic acne) Acne fulminans (acute febrile ulcerative acne) Acne keloidalis nuchae (acne keloidalis, dermatitis papillaris capillitii, folliculitis keloidalis, folliculitis keloidis nuchae, nuchal keloid acne) Acne mechanica Acne medicamentosa Acne miliaris necrotica (acne varioliformis) Acne vulgaris (acne simplex) Acne with facial edema (solid facial edema) Blepharophyma Chloracne Erythrotelangiectatic rosacea (erythematotelangiectatic rosacea, vascular rosacea) Excoriated acne (acne excoriée des jeunes filles, Picker's acne) Glandular rosacea Gnathophyma Gram-negative rosacea Granulomatous facial dermatitis Granulomatous perioral dermatitis Halogen acne Hidradenitis suppurativa (acne inversa, pyoderma fistulans significa, Verneuil's disease) Idiopathic facial aseptic granuloma Infantile acne Lupoid rosacea (granulomatous rosacea, micropapular tuberculid, rosacea-like tuberculid of Lewandowsky) Lupus miliaris disseminatus faciei Metophyma Neonatal acne (acne infantum, acne neonatorum, neonatal cephalic pustulosis) Occupational acne Oil acne Ocular rosacea (ophthalmic rosacea, ophthalmorosacea) Otophyma Periorificial dermatitis Persistent edema of rosacea (chronic upper facial erythematous edema, Morbihan's disease, rosaceous lymphedema) Phymatous rosacea Pomade acne Papulopustular rosacea (inflammatory rosacea) Perifolliculitis capitis abscedens et suffodiens (dissecting cellulitis of the scalp, dissecting folliculitis, perifolliculitis capitis abscedens et suffodiens of Hoffman) Perioral dermatitis Periorbital dermatitis (periocular dermatitis) Pyoderma faciale (rosacea fulminans) Rhinophyma Rosacea (acne rosacea) Rosacea conglobata Synovitis–acne–pustulosis–hyperostosis–osteomyelitis syndrome (SAPHO syndrome) Steroid rosacea Tar acne Tropical acne
A number of drug interactions can occur between MDMA and other drugs, including serotonergic drugs. MDMA also interacts with drugs which inhibit CYP450 enzymes, like ritonavir (Norvir), particularly CYP2D6 inhibitors. Life-threatening reactions and death have occurred in people who took MDMA while on ritonavir. Bupropion, a strong CYP2D6 inhibitor, has been found to increase MDMA exposure with administration of MDMA. Concurrent use of MDMA with certain other serotonergic drugs can result in a life-threatening condition called serotonin syndrome. Severe overdose resulting in death has also been reported in people who took MDMA in combination with certain monoamine oxidase inhibitors (MAOIs), such as phenelzine (Nardil), tranylcypromine (Parnate), or moclobemide (Aurorix, Manerix). Serotonin reuptake inhibitors (SRIs) such as citalopram (Celexa), duloxetine (Cymbalta), fluoxetine (Prozac), and paroxetine (Paxil) have been shown to block most of the subjective effects of MDMA. Norepinephrine reuptake inhibitors (NRIs) such as reboxetine (Edronax) have been found to reduce emotional excitation and feelings of stimulation with MDMA but do not appear to influence its entactogenic or mood-elevating effects. MDMA induces the release of monoamine neurotransmitters and thereby acts as an indirectly acting sympathomimetic and produces a variety of cardiostimulant effects. It dose-dependently increases heart rate, blood pressure, and cardiac output.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.